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Introduction: Despite widespread use of second-generation cholinesterase inhibitors for the symptomatic treatment
of Alzheimer’s disease (AD), little is known about the long term effects of cholinergic treatment on global cognitive
function and potential specific effects in different cognitive domains. The objectives of this study were to determine
the association between cholinergic treatment and global cognitive function over one and two years in a cohort of
patients with mild or moderate AD and identify potential differences in domain-specific cognitive outcomes within this
cohort.
Methods: A cohort of patients meeting the revised National Institute of Neurological and Communicative Disorders
and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for mild or
moderate AD, including patients both on treatment with a cholinesterase inhibitor and untreated controls
(treated = 65, untreated = 65), were recruited from the Cognitive Neurology Clinic at Sunnybrook Health
Sciences Centre, as part of the Sunnybrook Dementia Study. Patients were followed for one to two years and
underwent standardized neuropsychological assessments to evaluate global and domain-specific cognitive
function. Associations between cholinesterase inhibitor use and global and domain-specific cognitive outcome
measures at one and two years of follow-up were estimated using mixed model linear regression, adjusting for
age, education, and baseline mini mental state examination (MMSE).
Results: At one year, treated patients showed significantly less decline in global cognitive function, and treatment and
time effects across tests of executive and visuospatial function. At two years, there was a significant trend towards less
decline in global cognition for treated patients. Moreover, treated patients showed significant treatment and time
effects across tests of executive functioning, memory, and visuospatial function.
Conclusions: The present study offers two important contributions to knowledge of the effectiveness of cholinesterase
inhibitor treatment in patients with mild-moderate AD: 1) that second-generation cholinesterase inhibitors demonstrate
long-term effectiveness for reducing global cognitive decline over one to two years of follow-up, and 2) that decline in
function for cognitive domains, including executive function, memory, and visuospatial skill that are primarily mediated
by frontal networks and by the cholinergic system, rather than memory, may be slowed by treatment targeting the
cholinergic system.Introduction
Alzheimer’s disease (AD) affects more than 35 million
people worldwide [1,2] and is the most common form of
dementia in older people. Memory impairment is one
of the essential and earliest manifestations of AD [3-5],
and accompanying deficits include difficulties with* Correspondence: pearl.behl@gmail.com
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unless otherwise stated.word finding [2], visuospatial [6] and executive function
impairment [7].
AD is classified as one of the cortical dementias and,
although the etiopathogenesis of the disease remains
undefined, deficits in memory and cognition have previ-
ously been associated with cholinergic deficits in both
the hippocampus and cerebral cortex [8]. Randomized
double-blind, placebo-controlled trials of three second-
generation cholinesterase inhibitors (ChEIs) – donepezil,
rivastigmine, and galantamine – that enhance synaptic. This is an Open Access article distributed under the terms of the Creative
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est beneficial treatment effects in mild to moderate AD
over 6 to 12 month periods [9-13]. However, two major
gaps regarding treatment targeting the cholinergic system
that have previously not been addressed in randomized
trials relate to the short duration of follow-up for treat-
ment effects and the lack of information on specific
cognitive domains.
Most clinical trials have only examined patients over
shorter term periods of follow-up, so the duration of
treatment effects have not been well characterized [14,15].
The reasons for this are related primarily to the disease
process itself: it is difficult to conduct symptomatic treat-
ment studies in a relentlessly progressive neurodegenera-
tive disorder such as AD over time periods longer than
6 months within the context of a clinical trial because,
given the efficacy shown with ChEIs, longer term placebo
groups may no longer be considered ethical. Longer
follow-up periods of up to 18 months are being pursued
in trials with disease-modifying potential, with the experi-
mental treatment being added on to stable approved
symptomatic therapy.
Another issue has been whether treatment benefits are
disabled in trials of longer duration. Four industry-
sponsored, double-blind, placebo-controlled trials have
investigated the efficacy of continued ChEI treatment
over 1 year [16-18] and 2 years [19] of follow-up. These
studies demonstrated significant benefits, but only global
cognition was evaluated in treated patients [16,17]. A
nonpharmaceutical-sponsored, randomized, double-blind
trial investigating the effects of donepezil over 2 years also
revealed less decline in overall cognition and activities
of daily living in mild to moderate AD associated with
treatment [19]. However, this trial was limited by a large
dropout rate for patients (40% at the end of 1 year and
77% at the end of 2 years).
The interpretation of available data from even longer
term trials is difficult, since these are open-label exten-
sions [20] also confounded by large dropout rates and
the bias that comes from patient self-selection. A natural
history extrapolation using the Stern equation is typically
used for comparison instead of real data [21]. More re-
cently, ChEIs have been the open-label comparator for
some newer putative disease-modifying therapy trials,
which include untreated patients who provide a true
placebo comparison but are a small subset of the overall
trial population [22,23]. Most studies use the last observa-
tion carried forward, a flawed approach when the object-
ive is to investigate slower progression and decline [24].
One possible method for obtaining important longer term
outcome information is to employ well-conducted longi-
tudinal cohort studies [25].
A second limitation of previous studies has been the
emphasis on global cognitive outcome measures, withlittle information on domain-specific cognitive outcomes.
Separate dissociable neuropsychological impairments have
been shown in AD, yet it is unknown whether attention,
executive, memory, visuospatial, and language functions
are all equally likely to benefit from a particular pharmaco-
therapy, and there are currently no randomized controlled
trial data assessing treatment effects on performance for
specific cognitive domains. Of particular importance are
executive functions, which have previously been correlated
with instrumental activities of daily living [26] and may be
particularly responsive to cholinergic agents, given the
known effects of the cholinergic system on selective atten-
tion [27,28]. Preliminary findings in a previous study from
our group indicated that executive, language and visuo-
spatial functions, as indexed by the Mattis Dementia
Rating Scale (DRS) [29] and its five subscores, rather
than memory, appeared more amenable to stabilization
by ChEIs in AD over 1 year [30]. Given the natural
course of AD degeneration over several years, it is essential
to assess the potential benefits of ChEIs over time periods
longer than 6 months to evaluate whether these drugs have
lasting effects in AD patients. Of equal importance is the
assessment of treatment benefits for different cognitive
domains, to identify potential domain-specific differences
in treatment response in this clinical population.
The present study sought to address these gaps in the
knowledge of the effects of cholinesterase therapy in
mild or moderate AD. The primary objective was to
examine the association between treatment with ChEIs
and global cognitive function over 1 year and 2 years of
follow-up in mild or moderate AD patients. The second-
ary objective was to evaluate domain-specific cognitive
performance over this longer term follow-up period, to
determine whether specific domains are differentially
affected in mild or moderate AD patients treated with
ChEIs compared with untreated patients.
Methods
Cohort selection
One-hundred and thirty patients (untreated = 65, treated =
65) meeting the revised National Institute of Neurological
and Communicative Disorders and Stroke–Alzheimer's
Disease and Related Disorders Association criteria for mild
(baseline Mini-Mental Status Examination (MMSE) 20–30)
or moderate (baseline MMSE 10–19) probable AD [31]
were recruited from the Cognitive Neurology Memory
clinic at Sunnybrook Health Sciences Centre, a University
of Toronto academic healthcare institution, for the period
from 1993 to 2002. Inclusion and exclusion criteria for the
study cohort have been described previously [30,32]. This
study had ethical approval from the Sunnybrook Research
Ethics Board (REB PIN: 009–1998) and all patients
selected for the study cohort provided informed consent
prior to participation. Details regarding selection procedures
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publications [30,32].Study variables and procedures
All patients underwent a standardized neuropsychological
protocol at baseline and 1 year of follow-up, with a subset
of patients also assessed at a 2-year follow-up session.
The primary outcome was performance on standardized
measures of global cognitive function, described below.
Secondary outcomes included performance on multiple
measures of domain-specific cognitive function.
Demographic variables included: age; sex; education,
which was categorized as elementary (0 to 6 years), high
school (7 to 12 years), and post-secondary (≥13 years);
and baseline score on the MMSE, categorized into mild
(≥20) and moderate (10 to 19) categories. To minimize
the potential impact of bias due to losses to follow-up,
baseline demographics of all patients diagnosed with mild
or moderate probable AD who began treatment between
1997 and 2002 were examined and lost observations were
compared with those who stayed on therapy and were
followed to the study endpoint. To minimize the potential
for bias associated with the use of a historical control
cohort, data on potential confounding variables including
use of concomitant medications, presence of comorbid
illnesses, vascular risk factors (hypertension, diabetes mel-
litus, hyperlipidemia, smoking), family history of stroke,
and the presence of vascular end-organ damage were pro-
spectively ascertained for all patients and validated by a
second review of clinic charts [30]. Mean depressive symp-
tomatology scores from the Cornell Scale for Depression in
Dementia [33] for were obtained for all patients and con-
comitant use of selective serotonin reuptake inhibitors was
carefully documented.Treatment
All of the patients included in the study cohort were
enrolled in a longitudinal observational study, the Sunny-
brook Dementia Study [ClinicalTrials.gov:NCT01800214],
using the same standardized protocol either prior to the
approval of ChEIs (no-treatment cohort) or after treat-
ment (treatment cohort) became a common clinical op-
tion. Once cholinergic therapy was available, all patients
with mild to moderate probable AD were offered treat-
ment, if not contraindicated, and titrated as recommended
to a maximum tolerated dose (achieved in >90% of patients
in the study).Neuropsychological assessment protocol
Global cognition
Global cognitive function was assessed using the MMSE
[34] and the total score from the DRS [29].Domain-specific cognition
Memory function was assessed using the California Verbal
Learning Test (acquisition, and short and long delay free
recall subscores) [35], delayed visual reproduction [36],
and the memory subscore of the DRS [29]. The Backward
Digit Span task was included as a measure of working
memory function [36]. Executive functioning was indexed
with several measures, including the Controlled Word
Association Test using the letters F, A and S (phonemic
fluency, correct) [37], Semantic Fluency for animals
(words correct) [37], Wisconsin Card Sort Test (number
correct, denoting the number of categories correctly
completed) [38], Trails B (time in seconds) [39], and the
attention, conceptualization and initiation/perseveration
subscores of the DRS [29]. Trails A (time in seconds)
was used to measure speed of processing. Language
function was assessed using the Boston Naming Test
(30-word version) [40]. Visuospatial attention and visuo-
constructive skill were measured with the Rey–Osterreith
Complex Figure Test [41], the Benton Line Orientation
Test [42], and the construction subscore of the DRS [29].
Statistical analyses
Paired-sample t tests and chi-square analyses were used
to compare treated and untreated patients with respect
to all continuous and categorical demographic variables
at baseline (see Table 1). Critical values for significance
were corrected for multiple comparisons using the Holm
correction [43], a sequentially rejective Bonferroni method
to maintain the experiment-wise error rate.
Treatment effect sizes (Cohen’s d) were calculated as
standardized response means for all patients at both the
1-year and 2-year follow-up endpoints:
Tt2‐t1−Ut2‐t1ð Þ
SDð Þpooled
where T is the treated group, U is the untreated group, t2
is the follow-up, t1 is the baseline, and SDpooled are the
standard deviations of the change scores for the two groups
(Cohen’s criteria: 0.2 = small effect size, 0.5 = moderate
effect size, 0.8 = large effect size).
Associations between treatment with ChEIs and cogni-
tive outcome measures were estimated using multivariable
mixed-model linear regression, with separate models de-
rived for all cognitive outcomes at 1 year and 2 years of
follow-up. All final models were adjusted for age, educa-
tion, and baseline MMSE score.
Results
Mean follow-up times for the 1-year assessment were
14.4 months for untreated patients and 14.6 months for
treated patients. Mean follow-up times for the 2-year
assessment were 25.2 months for untreated patients and
Table 1 Baseline characteristics for treated (n = 65) and untreated (n = 65) patients with mild–moderate Alzheimer’s
disease
Factor Untreated Treated χ2 / t statistic (df) P valuea
Males/females 32/33 36/29 0.50 (1) 0.50
Age 71.4 ± 8.4 71.9 ± 9.9 0.70 (128) 0.70
Education (years) 13.5 ± 3.5 13.3 ± 3.9 0.50 (128) 0.50
Handedness 0.40 (1) 0.80
Right 60 63
Both 5 2
Handedness 2 0.021 (1) 0.90
Right 32 55
Both 2 3
Symptom duration (years) 3.5 ± 2.3 2.8 ± 2.3 0.11 (128) 0.80
Mini-Mental State Examination 22.4 ± 3.7 23.1 ± 3.6 1.1 (128) 0.30
Dementia Rating Scale 116.8 ± 11.0 118.8 ± 14.3 0.98 (128) 0.32
Disability Assessment for Dementia 78.9 ± 15.9 82.8 ± 17.3 0.10 (128) 0.90
Instrumental activities of daily living 65.9 ± 25.2 72.2 ± 24.6 0.10 (128) 0.92
Basic activities of daily living 95.8 ± 5.9 95.2 ± 9.1 1.90 (128) 0.06
BEHAVE-AD 5.3 ± 3.6 5.6 ± 6.5 0.20 (128) 0.80
Hypertension 24 16 2.3 0.10
Hyperlipidemia 9 11 0.80





Family history of stroke 10 13 0.65
Cerebrovascular disease 4 8 0.36
Cardiac disease 11 8 0.60
Peripheral vascular disease 5 1 0.21
Chronic respiratory, gastrointestinal and genitourinary disease 36 47 1.90 0.20
Depressive symptoms (not due to primary psychiatric illness) 0 3 0.20
Neurological problems (for example, migraines) 8 14 0.20
Endocrine/metabolic deficiency/infectious diseases 10 7 0.60
Chemical exposure 4 1 0.40
Ear–nose–throat 15 16 1.00
Cancer 7 9 0.80
Musculoskeletal disease 19 25 1.2 0.27
Statins 8 7 1.00
Selective serotonin reuptake inhibitors 9 17 0.12
Cardiovascular 23 19 0.56 0.45
Antithrombotics 22 22 0.0 1.00
Non-steroidal anti inflammatory drugs 4 2 0.68
Antipsychotics 1 0 1.00
Anticonvulsants 3 5 0.72
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Table 1 Baseline characteristics for treated (n = 65) and untreated (n = 65) patients with mild–moderate Alzheimer’s
disease (Continued)
Diabetes 3 2 1.00
Hormone replacement therapy 8 9 1.00
Thyroid 9 8 1.00
Data presented ± standard deviation unless otherwise stated. Fisher’s exact test was used for cells with counts ≤15. BEHAVE-AD, Behavioural Pathology in Alzheimer's
Disease; df, degrees of freedom. aCritical values corrected for multiple comparisons (Holm’s correction) – no significant difference.
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differences in mean follow-up between treated patients
and untreated patients at either time point.
Baseline demographics and characteristics are provided
in Table 1. No significant differences were observed be-
tween treated patients and untreated patients for baseline
demographic variables, baseline neuropsychological per-
formance, nonvascular and vascular disease burden indi-
ces at baseline or at follow-up, body system or chemical
exposure, alcohol use, allowable neurological problems
(such as history of migraine), or remote history of de-
pressive symptoms. Patients also did not differ in terms
of cerebrovascular, cardiac, or peripheral vascular disease
prevalence, or in use of concomitant medications includ-
ing statins, antihypertensives and hypoglycemic agents at
baseline or follow-up (see Table 1).
Primary outcomes
Mean scores on the MMSE and the DRS total for
treated patients and untreated patients at baseline and at
the 1-year and two-year assessments, and effect size esti-
mates, are presented in Table 2. Results of mixed linear
regression modeling demonstrated significant differences
in global cognitive function over time between treated
patients and untreated patients. Specifically, treated pa-
tients showed significantly less decline from baseline to
the 1-year assessment than untreated patients on both the
MMSE (interaction: ß = 2.58, 95% confidence interval
(CI) = 0.42 to 4.74, P = 0.02) (see Figure 1) and the DRS
total score (interaction: ß = 8.61, 95% CI = 1.27 to 15.94,
P = 0.02) (see Figure 2), after adjusting for age andTable 2 Mean (standard deviation) and effect size estimates f






DRS total Baseline 120.5
1 year 116.7
2 years 104.8
DRS, Dementia Rating Scale; MMSE, Mini-Mental State Examination.educational status. Although significant differences in
MMSE score were also observed between baseline and
the 2-year assessment across treatment status (main effect:
ß = 26.14, 95% CI = 16.85 to 35.44, P < 0.01), differences
between treated patients and untreated patients over time
on this measure did not reach significance in the adjusted
model (interaction: P = 0.11). Similarly, significant differ-
ences were also observed between baseline and the 2-year
assessment across treatment status for the DRS total score
(main effect: ß = 6.53, 95% CI = 4.23-8.82, P < 0.01), but
these differences only trended towards significance by treat-
ment status in the adjusted model (interaction: P = 0.08)
(Figures 1 and 2).
Secondary outcomes
Mean scores on all domain-specific cognitive measures
for treated and untreated patients at baseline and at the
1-year and 2-year assessments, and effect size estimates,
are presented in Table 3. Owing to a high proportion of
missing observations (reflecting task difficulty), data for
the California Verbal Learning Test and Trails A and
Trails B measures were not included in these analyses.
Overall, results for the secondary outcomes at the 1-year
follow-up assessment showed significant differences
between treated patients and untreated patients across
time-points on measures of executive function and
visuospatial attention and visuoconstructive skill, and
significant differences between baseline and 1-year follow-
up across treatment status on measures of executive func-
tion; however, no significant interactions between treatment
and time at 1 year were present in the adjusted models foror global measures of cognitive function over time in
r’s disease
Mean (standard deviation) Effect size
eated Untreated (Cohen’s d)
3 (3.3) 22.9 (4.1)
1 (4.1) 20.7 (5.2) 0.7
2 (5.5) 16.4 (7.6) 0.5
(15.1) 117.9 (12.0)
(17.1) 110.0 (18.3) 0.7
(24.2) 91.8 (29.7) 0.5
Figure 1 Change in mean Mini-Mental Status Examination over time and estimate of treatment effect for treated and untreated patients
with mild–moderate Alzheimer’s disease. CI, confidence interval; MMSE, Mini-Mental Status Examination.
Figure 2 Change in mean Dementia Rating Scale total score over time and estimate of treatment effect for treated and untreated
patients with mild–moderate Alzheimer’s disease. CI, confidence interval; DRS, Dementia Rating Scale.
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Table 3 Mean (standard deviation) and effect size estimates for domain-specific measures of cognitive function over
time in treated and untreated patients with mild–moderate Alzheimer’s disease
Measure Assessment Mean (standard deviation) Effect size
Time Treated Untreated (Cohen’s d)
DRS attention Baseline 34.5 (3.2) 35.1 (2.0)
1 year 33.6 (3.9) 33.6 (3.9) 0.50
2 years 31.7 (5.2) 30.2 (7.8) 0.40
DRS initiation Baseline 29.6 (6.1) 27.2 (6.2)
1 year 28.6 (6.5) 25.4 (7.8) 0.51
2 years 24.6 (9.2) 19.6 (8.7) 0.50
DRS construction Baseline 5.0 (1.2) 5.4 (1.4)
1 year 5.0 (1.3) 4.9 (1.8) 0.52
2 years 4.3 (1.7) 4.4 (2.0)
DRS conceptualization Baseline 33.3 (5.8) 34.2 (3.8)
1 year 34.4 (4.6) 32.0 (6.3) 0.53
2 years 31.4 (7.1) 27.2 (10.5) 0.60
DRS memory Baseline 16.9 (4.0) 15.8 (4.3)
1 year 15.5 (4.2) 14.1 (4.0)
2 years 12.3 (5.0) 10.4 (4.1)
VR2 Baseline 3.4 (5.9) 4.4 (5.6)
1 year 3.0 (5.4) 1.6 (3.8)
2 years 1.7 (5.4) 1.3 (2.6)
BDS Baseline 5.3 (2.2) 5.1 (2.5)
1 year 4.9 (2.1) 4.5 (2.4) 0.40
2 years 4.9 (2.5) 3.9 (2.5) 0.50
REY Baseline 25.7 (9.0) 25.5 (10.8)
1 year 25.1 (10.1) 21.4 (13.8) 0.5
2 years 22.1 (10.6) 17.2 (24.2)
Benton Line Orientation Test Baseline 20.6 (7.6) 19.8 (9.1)
1 year 18.8 (9.8) 17.2 (9.7)
2 years 17.7 (9.5) 16.1 (10.3)
WCST Baseline 41.5 (8.3) 36.9 (7.7)
1 year 41.3 (8.8) 35.3 (10.3)
2 years 36.6 (9.3) 32.6 (10.1)
Boston Naming Test Baseline 22.2 (5.4) 20.9 (6.3)
1 year 20.3 (6.7) 17.5 (7.5) 0.50
2 years 18.7 (8.3) 13.3 (8.5) 0.60
Semantic Fluency Baseline 12.4 (4.4) 10.1 (4.3)
1 year 10.6 (5.1) 7.9 (4.2)
2 years 8.9 (4.2) 5.8 (4.0)
FAS Baseline 31.6 (12.7) 24.8 (11.6)
1 year 30.3 (11.6) 21.3 (13.2) 0.73
2 years 24.0 (11.8) 17.6 (12.1)
BDS, Backward Digit Span; DRS, Dementia Rating Scale; FAS Controlled Word Association Test; REY, Rey–Osterreith Complex Figure Test; VR2, delayed visual
reproduction; WCST Wisconsin Card Sort Test.
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significant differences between treated patients and un-
treated patients were observed across time from baseline
to 1 year on the Wisconsin Card Sorting Test (main effect:
ß = 3.76, 95% CI = 0.03 to 7.49, P = 0.05) and the Benton
Line Orientation Test (main effect: ß = 3.88, 95% CI = 0.01
to 7.78, P = 0.05). Significant differences from baseline to
1-year follow-up across treatment status were also observed
for the Semantic Fluency task (main effect: ß = 1.49. 95%
CI = 0.02 to 2.95, P = 0.04).
At the 2-year follow-up assessment, results showed a
significant difference between baseline and the 2-year
assessment across treatment status on a measure of
executive function, and trends towards significance by
treatment and by time for several domains, including
executive function, memory, visuospatial attention, and
visuoconstructive skill. Specifically, significant differences
between treated patients and untreated patients were
observed across time from baseline to 2 years on the
Semantic Fluency test (main effect: ß = 1.78, 95% CI = 0.23
to 3.34, P = 0.02). Trends towards significant main effects
for treatment status across time were observed for the
attention (P = 0.08) and construction (P = 0.06) subscores
of the DRS, the Controlled Word Association Test
(P = 0.06), and the Semantic Fluency test (P = 0.09).
Trends towards significant main effects for time across
treatment status were observed for the attention (P = 0.10)
and memory (P = 0.07) subscores of the DRS, and for the
Controlled Word Association Test (P = 0.10). No signifi-
cant interactions between treatment and time at 2 years
and no significant main effects were present in the ad-
justed models for any of the other domain-specific cogni-
tive measures.
Discussion
The purposes of this study were to evaluate the effect of
treatment with a ChEI on long-term global and domain-
specific cognitive performance in patients with mild to
moderate AD. To our knowledge, this observational cohort
study represents the first to assess longer-term cognitive
performance across multiple cognitive domains using a
detailed, standardized neuropsychological battery for each
of these treatment groups. Findings of this study indicated
that treated patients with mild or moderate AD showed
slower decline in global cognitive function over 1 year and
a trend towards slower decline over 2 years, as compared
with untreated AD patients. In addition, secondary ana-
lyses indicated that performance on tasks requiring the
domains of executive function, memory, visuospatial at-
tention, and visuoconstructive skill differed either between
groups or over time in this cohort, suggesting that, in
addition to memory, other specific cognitive domains may
be selectively responsive to long-term cholinesterase treat-
ment in mild to moderate AD patients. The present studythus offers two important contributions to knowledge of
the effectiveness of ChEI treatment in this clinical popu-
lation: second-generation ChEIs demonstrate long-term
effectiveness for reducing global cognitive decline over
1 to 2 years of follow-up; and decline in function for
several cognitive domains, including executive function,
memory, and visuospatial skill, may be slowed by treat-
ment targeting the cholinesterase system.
The findings of the present study are consistent with
data from previous 6-month pivotal clinical trials and
provide further evidence to support the benefit of ChEI
treatment for global cognitive function in patients with
mild–moderate AD. Although the short-term effective-
ness of second-generation ChEIs has been demonstrated
previously in double-blind, placebo-controlled trials, few
data were available evaluating the effectiveness of ChEIs
over 1 and 2 years. In comparison with untreated AD
patients, treated patients in the current study demonstrated
significantly less decline in global cognitive function, as
measured using the MMSE and DRS, over a 1-year period
and trends towards less decline over 2 years. Further, these
benefits exhibited moderate effect sizes, greater in many
instances than those of the Alzheimer’s Disease Assessment
Scale – cognitive subscale differences in the 6-month
pivotal trials [44], and were present for the DRS, which is
a more sensitive measure of cognitive progression across a
broader disease spectrum in patients with AD [45]. These
findings have implications for the use of treatment target-
ing the cholinesterase system in patients with mild to
moderate AD, and suggest that these patients may benefit
from long-term treatment with ChEIs to slow the progres-
sion of cognitive impairment.
Several factors support the validity and comparability
of our patients with previous randomized clinical trial
populations. Our patients were similar with respect to
average age and education, but had a slightly higher
mean MMSE scores at baseline than the pivotal trials. The
literature shows an average annual decline in untreated
AD patients of 2 to 4 points for the MMSE [46]. Our data
showed a decline of 3.6 points over a 1-year period in
the untreated patients. This is also comparable with the
untreated controls in the cohort of Lopez and colleagues,
who showed a 4-point decline over 1 year [25]. Further-
more, our study showed a decline of 0.9 points on the
MMSE in the treated group, which is also comparable
with the year-long, placebo-controlled, randomized clin-
ical trials that ranged from an improvement of 1 point to
a decline of 2 points in the treated patients depending on
baseline disease severity [16-19,25,47]. The results of the
present study are hence consistent with previous data
from clinical trials with respect to the mean change in
MMSE score and suggest that trends toward slower
decline in treated patients may also persist up to 2 years
of follow-up.
Behl et al. Alzheimer's Research & Therapy 2014, 6:48 Page 9 of 12
http://alzres.com/content/6/4/48The present study also extends findings of previous
double-blind, randomized, placebo-controlled trials [17-19]
by providing information to characterize potential differ-
ences in treatment effects for specific cognitive domains.
Unlike prior work, analyses of secondary outcomes in the
present study indicated that the cognitive domain primar-
ily responsive to treatment in AD patients was executive
function, not memory, with significant main effects
observed for both treatment status and time on several
measures of executive function. In vivo studies using
structural brain imaging have shown significant correla-
tions between severity of hippocampal damage and de-
layed recall measures on the California Verbal Learning
Test [48] and the memory subscale of the DRS [49]. The
early isolation of the hippocampus from other regions
and the resulting loss of basal forebrain cholinergic pro-
jections are thought to be key neural substrates for the
severe memory deficits observed in AD. Thus, increas-
ing synaptic concentrations of acetylcholine may be less
effective in medial temporal cortices, which are selectively
vulnerable to AD pathology and may already demonstrate
major pathology by the time of clinical symptom onset.
This is consistent with findings from our study, as treated
patients did not show beneficial differences on tasks of
memory function, including the DRS memory subscore,
as compared with untreated patients over 1 and 2 years.
Cholinergic augmentation may have a greater impact on
the attentional system [7,50], such that tasks measuring
attention and executive dysfunction may show greater
sensitivity to ChEI treatment effects in AD patients than
those that measure memory. There is increasing evidence
from clinical studies to support this possibility. Previous
studies examining the effects of the cholinergic agonist
tacrine reported benefits in a five-choice attention task in
AD patients with improvements in speed and accuracy,
but not memory [51,52]. Further, data from one small
randomized controlled trial comparing 15 treated AD
patients with 20 placebo-treated patients showed less
decline for treated patients on the Backward Digit Span
over 1 year [53], and a previous Japanese cohort study
comparing 47 AD patients treated with ChEIs with 61
untreated patients showed less decline in treated patients
in concept formation and abstract thinking skills over
10 months [54].
In the present study, treated patients and untreated
patients differed significantly at baseline and 1 year in
performance on the Wisconsin Card Sorting Test, pro-
viding further support for the benefit of ChEI treatment
for executive functions involving selective strategic
planning and organization, goal-directed behavior, and
cognitive shift setting. In addition, trends towards signifi-
cant differences by treatment status were also present
for the attentional and constructional subscores of the
DRS at 2 years, suggesting the potential for long-termcholinesterase therapy to stabilize deficits in the ability
to attend to and execute verbal and visual commands
of varied complexity. These findings are consistent
with prior literature demonstrating the efficacy of ChEI
treatment for attentional and executive functions, and
provide further evidence to suggest that, given the fa-
cilitative effects of the cholinergic system on attention,
long-term treatment with ChEIs may offer benefits for
executive functioning in patients with mild–moderate
AD [55-63].
Visual–spatial and visuoconstructional impairment in
AD are also attributed to impaired executive functioning
[64,65]. Stabilization of performance on visuoconstructive
tasks, such as the Rey copy task, has previously been
shown in a small clinical study of 15 AD patients treated
with a ChEI compared with 20 placebo-treated control pa-
tients [53]. Although results of the present study showed
no differences between patients on performance for the
Rey copy task, a significant main effect of treatment status
was observed at 1 year for the Benton Line Orientation
Test, another task involving visual–spatial and visuocon-
structive skill, suggesting that these networks may also be
selectively responsive to treatment targeting the choliner-
gic system.
Tasks of verbal fluency provide a measure of encoding
deficits associated with an inability to utilize semantic
knowledge to characterize words and assist in learning
[66-68] characteristic of early AD [69-71]. For instance,
hippocampal atrophy has previously been correlated
with recall on a list-learning task and has been associ-
ated with reduced memory-enhancing effects of ChEIs
[52]. Similarly, in a recent study using the CERAD word
list learning test, (The Consortium to Establish a Regis-
try for Alzheimer's Disease) 14 AD patients treated with
ChEIs showed no difference in delayed free recall com-
pared with 14 untreated patients, but treated patients
made fewer errors on a recognition test [72]. Results from
our study showed significant main effects by both treat-
ment status and time at 1 and 2 years on the semantic
fluency task and an additional trend for main effects of
treatment and time at 2 years on the Controlled Word
Association Test, a task of phonemic fluency. These find-
ings indicate that, despite the potential for hippocampal
pathology in patients with mild–moderate AD, benefits
may still be provided by ChEI treatment for the strategic
processes involved in verbal fluency [73-77].
Although randomized controlled trials are considered
the gold standard for comparing the efficacy of cholin-
esterase therapies in patients with neurodegenerative
conditions, such as AD, these trials are limited by ethical
and practical issues with randomization. Observational
cohort studies provide an alternative methodology for the
investigation of long-term treatment effects in this clinical
population. The present study followed treated patients
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to 2 years and also explored domain-specific cognitive
functioning, minimizing the limitations of longer random-
ized controlled trials (ethics of a placebo group; significant
dropout). Despite these strengths, the present study also
had limitations. Losses to follow-up were a factor in the
present study, limiting our ability to explore the effects of
treatment for some cognitive measures. However, the use
of mixed-model analytic techniques minimized the impact
of these losses and enabled us to examine function across
several cognitive domains. It is also important to note that
the use of historical control groups is subject to biases,
such as selection bias and the Flynn effect, which may
have impacted these analyses. Although the Flynn effect
can influence the comparison of cohorts from different
time periods, the potential for this bias was minimal in the
present study, as the time gap between intake procedures
for patients selected for this cohort was very short (1993
to 1996 for untreated patients and 1997 to 2002 for
treated patients). The short time gap for cohort selection
also reduced potential biases due to changes in the preva-
lence of comorbid conditions that may have occurred over
the study period. Further, the potential for selection biases
were also minimized in the present study, via the ascer-
tainment, validation, and comparison of groups within the
study cohort on several potential confounding factors.
However, it is possible that, despite these methods, re-
sidual biases associated with the use of a historical control
remained.
Conclusions
Findings from our study provide evidence that treatment
with ChEI offers significant long-term benefits for global
cognitive function in patients with mild to moderate
AD. Observations of stabilization in performance on tasks
of executive, attentional, visuospatial, and visuoconstruc-
tive functions [78-80] across time and treatment also
suggest that ChEIs may selectively preserve function for
these specific cognitive domains. It is important to note
that executive functions, mediated by frontal regions, ra-
ther than memory, showed greater potential response to
ChEI in this cohort. These findings have implications for
the identification of regions with potential differential cap-
acities for response to cholinergic therapies. As efforts to
identify disease-modifying treatments with the ability to
slow or interrupt early pathologic changes, prevent disease
progression, and alter the natural course and outcome of
AD have been unsuccessful to date [23], further research
is required to optimize therapeutic strategies for patients
with AD. This study offers important insights into the
cognitive domains that show potential response to treat-
ment targeting the cholinergic system and suggests that
future studies would benefit from a more comprehensive
evaluation of domain-specific cognitive functions, includingprotocols for the assessment of attention and executive
dysfunction, to further elucidate which cortical net-
works may benefit from long-term treatment with
second-generation ChEIs in patients with mild to mod-
erate AD.
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